+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

SAT0403Further Analysis of Psoriatic Arthritis Disease Activity Score (PASDAS) and Composite Psoriatic Disease Activity Index (CPDAI) Using Data from A Placebo-Controlled TRIAL of Certolizumab Pegol in Psoriatic Arthritis



SAT0403Further Analysis of Psoriatic Arthritis Disease Activity Score (PASDAS) and Composite Psoriatic Disease Activity Index (CPDAI) Using Data from A Placebo-Controlled TRIAL of Certolizumab Pegol in Psoriatic Arthritis



Annals of the Rheumatic Diseases 73(Suppl 2): 740.1-740




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 064565396

Download citation: RISBibTeXText

DOI: 10.1136/annrheumdis-2014-eular.1654


Related references

Gender does not make a difference in "composite psoriatic disease activity index (CPDAI)" in patients with psoriatic arthritis. Rheumatology International 38(11): 2069-2076, 2018

AB0930DAREA/DAPSA (disease activity score for reactive arthritis/disease activity index for psoriatic arthritis) and related variables in patients with psoriatic arthritis (PSA):. Annals of the Rheumatic Diseases 71(Suppl 3): 691.18-691, 2013

Modification of the Psoriatic Arthritis Disease Activity Score (PASDAS). Annals of the Rheumatic Diseases 77(3): 467-468, 2018

4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. Rmd Open 4(1): E000582, 2018

Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints?. Annals of the Rheumatic Diseases 77(12): 1736-1741, 2018

Development of a disease activity and responder index for psoriatic arthritis--report of the Psoriatic Arthritis Module at OMERACT 11. Journal of Rheumatology 41(4): 782-791, 2014

Disease activity and response assessment in psoriatic arthritis using the Disease Activity index for PSoriatic Arthritis (DAPSA). A brief review. Clinical and Experimental Rheumatology 33(5 Suppl 93): S48-S50, 2015

Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis. Arthritis Care and Research 70(12): 1764-1770, 2018

Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial. Clinical Rheumatology 37(12): 3285-3296, 2018

Early Disease Activity or Clinical Response as Predictors of Long-Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis. Arthritis Care and Research 69(7): 1030-1039, 2017

Patient-centered psoriatic arthritis (PsA) activity assessment by Stockerau Activity Score for Psoriatic Arthritis (SASPA). Bmc Musculoskeletal Disorders 16: 73, 2015

Clinical Characteristics, Disease Activity, and Patient-Reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. Arthritis Care and Research 69(11): 1692-1699, 2017

RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol. Arthritis Care and Research 63(8): 1142-1149, 2011

Clinical and ultrasonographic predictors for achieving minimal disease activity in patients with psoriatic arthritis: the UPSTREAM (Ultrasound in PSoriatic arthritis TREAtMent) prospective observational study protocol. Bmj Open 8(7): E021942, 2018

FRI0469Measuring Outcome in Psoriatic Arthritis (MOPSA), A New Web-Based Tool for Assessment of Psoriatic Arthritis Showing Initiation of Treatment Change in Patients Achieving Minimal Disease Activity. Annals of the Rheumatic Diseases 75(Suppl 2): 607.2-607, 2016